Nonarteritic anterior ischemic optic neuropathy is associated with a specific platelet polymorphism located on the glycoprotein Ibα gene

Non-arteritic anterior ischaemic optic neuropathy: A review and update

“…20 However, in a second study by the same authors the presence of a platelet glycoprotein polymorphism (the VNTR B allele of glycoprotein Ib-alpha) was found to confer a significant risk for NAION and predispose affected patients to second eye involvement. 39 Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities and has been shown to be protective against ischemic heart, cerebrovascular disease, and retinal vein occlusion. It has recently been discovered that G6PD deficiency is also protective against NAION.…”

Familial non-arteritic anterior ischemic optic neuropathy

“…In sharp contrast, Salomon et al [28] evaluated various genetic and acquired thrombophilic markers, including MTHFR C677T in 61 patients with classical NA-AION, and found no association between NA-AION and these thrombophilic factors. Association between one of the platelet glycoprotein polymorphisms and second eye involvement in NA-AION [29], and of vascular tone (endothelial nitric oxide synthase gene polymorphisms) with NA-AION [27] have recently been reported; however, those observations still need further confirmation. b. NA-AION is usually not a thromboembolic but a hypotensive disorder.…”

Large-scale identification of potential drug targets based on the topological features of human protein–protein interaction network

“…The P07359 is a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF and biological processes of blood coagulation, cell adhesion, hemostasis, cell surface receptor signaling pathway and thrombin receptor signaling pathway. Many studies [42][43][44] have demonstrated that the diseases of non-arteritic anterior ischemic optic neuropathy, Bernard-Soulier syndrome, pseudo-von Willebrand are related with the protein. These results imply that the molecular mechanism of three diseases may be associated with the biological processes of blood coagulation, cell adhesion, hemostasis, cell surface receptor signaling pathway and thrombin receptor signaling pathway, and the protein can be considered as drug target for treating these diseases.…”